

# Utility of BioGlue® surgical adhesive in preventing air leaks in lung volume reduction surgery (LVRS)

<b>Submission date</b> 26/02/2009	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 24/07/2009	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 12/07/2016	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data
		<input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

Not provided at time of registration

## Contact information

### Type(s)

Scientific

### Contact name

Mr Pala Rajesh

### Contact details

Consultant Thoracic Surgeon  
Regional Department of Thoracic Surgery  
Birmingham Heartlands Hospital  
Heart of England NHS Foundation Trust  
Bordesley Green East  
Birmingham  
United Kingdom  
B9 5SS  
+44 121 424 3561  
[pala.rajesh@heartofengland.nhs.uk](mailto:pala.rajesh@heartofengland.nhs.uk)

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

## Secondary identifying numbers

Version 2

# Study information

### Scientific Title

A controlled trial comparing stapling with BioGlue® surgical adhesive versus stapling with buttressed bovine pericardium in lung volume reduction surgery (LVRS)

### Study objectives

BioGlue® on staple line is as effective as stapling with pericardial buttressing in reducing air leaks in lung volume reduction surgery (LVRS). Phase 1 will establish the role and efficacy of BioGlue® in LVRS and phase 2 will compare its benefits over buttressed pericardial stapling.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Birmingham East North and Solihull Research Ethics Committee approved in July 2005 (ref: 05/Q2703/77). Amendment in January 2009.

### Study design

Randomised self-controlled trial

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Surgery for emphysema

### Interventions

Patients are randomised via sealed randomised envelopes opened on the day of surgery. Patients are then randomised to LVRS with two different adjuncts to staple line:

1. BioGlue®
2. Pericardial buttress

### Intervention Type

Other

## **Phase**

Phase IV

## **Primary outcome measure**

To demonstrate an increase in the frequency of an air leak free post-operative hospital course for patients receiving BioGlue® as a pneumostatic sealant as compared to patients receiving the pericardial buttressed stapling. Post-operatively, occurrence of air leaks will be assessed on a per patient basis, twice daily.

## **Secondary outcome measures**

1. Incidence of re-operation due to air leaks
2. Volume of fluid loss in chest tube drain
3. Time to air leak cessation
4. Incidence of complications/adverse events
5. Early (hospital discharge) mortality and late mortality (through final follow-up)

Measured twice daily.

## **Overall study start date**

01/09/2005

## **Completion date**

01/10/2010

# **Eligibility**

## **Key inclusion criteria**

1. Patients undergoing LVRS
2. Forced expiratory volume in one second (FEV1) less than 40%
3. FEV1/forced vital capacity (FVC) ratio less than 50% following challenges with beta 2 agonists /ipratropium bromide and a trial of oral corticosteroids
4. Residual volume of greater than 140%
5. Severe emphysema with heterogeneity ("target areas") documented on high resolution computed tomography (CT) scans
6. Less than 75 years of age, but greater than 18 years of age, either sex
7. Clinically stable for 1 month before entry to the study

## **Participant type(s)**

Patient

## **Age group**

Adult

## **Lower age limit**

18 Years

## **Sex**

Both

**Target number of participants**

25

**Key exclusion criteria**

1. Patients who do not consent to the trial
2. Patients with known hypersensitivity to albumin, bovine products, or glutaraldehyde
3. Patients who have been treated with an investigational product and have not completed the entire follow-up period for that investigational product
4. Patients who are unwilling or unable to complete all study evaluations

**Date of first enrolment**

01/09/2005

**Date of final enrolment**

01/10/2010

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

Consultant Thoracic Surgeon

Birmingham

United Kingdom

B9 5SS

**Sponsor information****Organisation**

Heart of England NHS Foundation Trust (UK)

**Sponsor details**

Birmingham Heartlands Hospital

Bordesley Green East

Birmingham

England

United Kingdom

B9 5SS

**Sponsor type**

Hospital/treatment centre

**Website**

<http://www.heartofengland.nhs.uk/>

**Funder(s)****Funder type**

Industry

**Funder Name**

CryoLife Europa Ltd (UK) - educational grant

**Results and Publications****Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration